TITLE

Amgen, Takeda's Lung Cancer Drug Stumbles in Phase III

PUB. DATE
April 2011
SOURCE
Bioworld Week;4/4/2011, Vol. 19 Issue 14, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the vascular endothelial growth factor (VEGF) inhibitor, motesanib from Amgen Inc. and Takeda Pharmaceutical Co. Ltd. failed to meet the overall survival improvement in its Phase III trial for non-small-cell lung cancer (NSCLC). It mentions that high early mortality rates were found in patients who took the drug as well as an increase in hemoptysis. Furthermore, the trial of the drug was continued in nonsquamous NSCLC only hoping it would show benefit in the population.
ACCESSION #
60167021

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics